MedPath

Investigating the Mechanisms of Mindfulness-based Cognitive Therapy (MBCT)

Not Applicable
Completed
Conditions
Major Depression (in Remission)
Interventions
Behavioral: Mindfulness-based Cognitive Therapy
Registration Number
NCT02226042
Lead Sponsor
University of Manchester
Brief Summary

This research will investigate the neuropsychological mechanisms underlying the eight-week Mindfulness-based Cognitive Therapy (MBCT) programme.

Participants in remission from depression will be seen pre- and post-MBCT to assess the underlying neuropsychological mechanisms. All will be followed-up over 12 months to assess the relationship of these neuropsychological changes with relapse risk.

The research will focus primarily on changes in self-compassion, rumination, attention and structural brain changes, with secondary focus on other mechanisms of emotional processing and memory.

Detailed Description

There will be three groups in total.

* The first group will take 36 participants in remission from major depression (rMDD) through the 8 week MBCT program.

* A control group of 36 rMDD participants will not receive the intervention.

* A group of never depressed healthy control participants will also be recruited.

Research visits for participants not undergoing MBCT will be separated by an 8 week gap.

All participants will be seen before and after the 8 weeks for completion of neuropsychological assessments and questionnaires.

rMDD participants will be followed up over the following 12 months to identify any predictors of relapse.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
112
Inclusion Criteria

Participants with remitted depression (rMDD):

  • At least two previous episodes of DSM-IV major depression in adulthood, diagnosed using the Mini International Neuropsychiatric Interview (M.I.N.I).
  • Full or partial remission for at least three months with two depressive episodes within the last five years.
  • A score of less than or equal to 12 on the Montgomery Asberg Depression Rating Scale (MADRS) mood assessment.
  • If on medication, no recent or planned major changes

Healthy volunteers:

  • In good psychological health screened with the M.I.N.I

All participants:

  • in good physical health (to reduce risk of confounding physical health problems).
  • sufficiently fluent in English to ensure valid understanding and completion of the tasks.
  • minimum I.Q level of 80 to ensure sufficient understanding of the neurocognitive tasks administered.
  • colour vision and acuity within normal/corrected to normal limits.

Exclusion criteria:

  • Any current mental health diagnosis (DSM-IV diagnosis including current major depression, bipolar disorder, psychosis, Obsessive Compulsive Disorder (OCD), substance abuse or dependence, eating disorders)
  • Physical health or neurological disorders that might interfere with the interpretation of the tasks, including a history of significant head injury.
  • In addition healthy volunteers will be without a history mental health disorders (DSM-IV)
  • Current or previous experience of mindfulness-based treatments or extensive cognitive behavioural treatment, or planned participation in psychological treatments during the key time for the study (between pre and post visits).
  • Planned major alteration in drug treatment for depression between pre and post visits.
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Mindfulness-based Cognitive TherapyMindfulness-based Cognitive TherapyIndividuals currently in remission from depression will choose to enter the Mindfulness-based Cognitive Therapy (MBCT) arm and undergo the 8 week MBCT group programme
Primary Outcome Measures
NameTimeMethod
Changes in self-compassion following MBCT measured by both neuropsychological and self-report measuresmeasured at baseline and post intervention (8 weeks post baseline) and at each follow-up visit (3 in total)

Two neuropsychological measures of self-compassion have been developed and will be administerat baseline and after MBCT/8 week gap (8 weeks post baseline). Self-report questionnaires will be administered before and after MBCT/8 week gap and at subsequent follow-up visits (3, 6, 12 months).

Secondary Outcome Measures
NameTimeMethod
Changes in levels of rumination following MBCT measured through both neuropsychological and self-report measuresmeasured at baseline and after the intervention/8 week gap (8 weeks post baseline) and at each follow-up visit (3 in total)

One neuropsychological measure of rumination has been developed and will be administered at baseline and immediately after MBCT/8 week gap (8 weeks post baseline).

Self-report questionnaires will be administered at baseline and after MBCT/8 week gap (8 weeks post baseline) and at subsequent follow-up visits (3,6,12 months).

Changes in attention regulation following MBCTmeasured at baseline and after the intervention/8 week gap (8 weeks post baseline)
Changes in brain structure following MBCTmeasured at baseline and after the intervention (8 weeks post baseline)

Trial Locations

Locations (1)

University of Manchester

🇬🇧

Manchester, Greater Manchester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath